<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-106734</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Study of use of pemetrexed in non-small cell lung cancer</dc:title>
<dc:description xml:lang="en">Objective To study the effectiveness and safety of pemetrexed in non-small cell lung cancer. Method Retrospective study (March 2006¨CMay 2008) of pemetrexed use. Information was obtained from the Access database belonging to the Pharmacy and Oncology Departments, the registry of external consultations and clinical histories. Data were analysed using SPSS software version 12.0. Quantitative variables are expressed as the median (minimum-maximum).Results The study included 44 patients (61.7 [39¨C77] years old), mostly male (86%), smokers or former smokers (80%) with predominantly epidermoid/squamous disease (46%) or adenocarcinoma, in a good functional state (86%) and in stage ¡ÝIII upon beginning pemetrexed treatment (93%). Prior treatment with taxanes and taxane treatment along with a prior history of neutropoenia were the criteria for changing to pemetrexed in 34.4% and 22.7% of the patients, respectively. None of the patients presented a complete or partial response: 18.2% showed disease stability and 81.8% showed disease progression. The main reasons for discontinuing pemetrexed were progression of the disease (54.5%) and worsening of symptoms (15.9%). Median survival after beginning chemotherapy was 22.2 months (ranging from 16¨C28.4) and 7.8 months (4.4¨C11.2) after beginning pemetrexed treatment. These last figures were significantly higher in women and those with an ECOG of 0 to 1. The most common adverse effects were weakness and neurotoxicity. Conclusion In each of the cases, pemetrexed was used as a second-line treatment or higher with a good safety profile. A complete or partial response was not reached in any of the cases, but survival after beginning pemetrexed was equal to or longer than that achieved in other studies (AU)</dc:description>
<dc:creator>Blasco-Segura, P</dc:creator>
<dc:creator>Ortega-Garcia, M. P</dc:creator>
<dc:creator>Villanueva-Herraiz, S</dc:creator>
<dc:creator>Camps-Herrero, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo Estudiar la efectividad y la seguridad del pemetrexed en el cancer de pulmon no microcitico. Metodo Estudio retrospectivo (marzo 2006¨Cmayo 2008) de utilizacion de pemetrexed. Se obtuvo la informacion de bases de datos Access de los Servicios de Farmacia y Oncologia, del registro de visitas a consultas externas y de la historia clinica. Los datos se analizaron con SPSS v12.0. Las variables cuantitativas se expresaron con la mediana (minimo-maximo). Resultados Fueron 44 pacientes (61,7 años [39¨C77]) la mayoria hombres (86%), fumadores/exfumadores (80%), histologia epidermoide/escamosa (46%) o adenocarcinoma (36%), con buen estado funcional (86%) y estadio iii o superior al inicio del tratamiento con pemetrexed (93%). El tratamiento previo con taxanos y este junto con la neutropenia previa fueron los criterios de cambio a pemetrexed en el 34,4 y el 22,7% de los pacientes, respectivamente. Ningun paciente presento respuesta completa o parcial; el 18,2% mostro enfermedad estable y el 81,8% progresion de la enfermedad, siendo los principales motivos de retirada del pemetrexed la progresion de la enfermedad (54,5%) y el empeoramiento clinico (15,9%). La mediana de supervivencia desde el inicio de la quimioterapia fue de 22,2 meses (16¨C28,4) y desde el inicio con pemetrexed fue de 7,8 meses (4,4¨C11,2), siendo esta significativamente mayor en las mujeres y de aquellos con valor 0-1 en la escala Eastern Cooperative Oncology Group. Los efectos adversos mas frecuentes fueron astenia y neurotoxicidad. Conclusion Pemetrexed se ha utilizado en todos los casos como segunda linea o superior con buen perfil de seguridad. En ningun caso se alcano respuesta completa o parcial, pero la supervivencia desde el inicio de pemetrexed iguala o supera a la de otros estudios (AU)</dc:description>
<dc:source>Farm Hosp;34(4): 194-203, Jul. -Ago. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-106734</dc:identifier>
<dc:title xml:lang="es">Estudio de utilizacion de pemetrexed en el cancer de pulmon no microcitico</dc:title>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d52438</dc:subject>
<dc:subject>^d29924</dc:subject>
<dc:subject>^d10797</dc:subject>
<dc:subject>^d4403</dc:subject>
<dc:subject>^d28096</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d31722^s22057</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d8352^s22057</dc:subject>
<dc:subject>^d23947</dc:subject>
<dc:subject>^d23925</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d967^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201008</dc:date>
</metadata>
</record>
</ibecs-document>
